A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Trial sites expanded: 0 → 5 locations
    • Start date changed from estimate of Sep 22, 2026 to Sep 1, 2026
  2. Trial status: Not Yet Recruiting to Recruiting Show 4 more changesShow less
    • Study sites: 0 to 5
    • Primary and study completion dates: Dec 19, 2029 to Dec 5, 2029
    • Start date changed from estimate of Sep 22, 2026 to Sep 1, 2026
    • Study title expanded, about 2 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Prostate Cancer
2,550 trials monitored
See 165 trials at risk
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.
Trial Details
NCT Number NCT07802704
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Neoplasms, Prostate
Related terms Prostatic Neoplasms
Enrollment 684 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov